{"links":{"html":"https://www.erudio.com/reports/dellphi-309-nct06745323","json":"https://www.erudio.com/reports/dellphi-309-nct06745323.json","markdown":"https://www.erudio.com/reports/dellphi-309-nct06745323.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"dellphi-309-06745323"}},"request":"https://www.erudio.com/contact?report=dellphi-309-06745323"},"offer":{"cited_commentary_sources":39,"verified_hcp_statements":206,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":25,"optional":true,"price_per_verified_person_usd":15,"price_usd":375,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"dellphi-309-nct06745323"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=dellphi-309-06745323","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/dellphi-309-nct06745323","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-27T23:08:53.447446Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":2},"aspects":[{"claim_count":8,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Proportion of participants with confirmed objective response to Tarlatamab"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Proportion of participants with complete response to Tarlatamab"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Proportion of participants with partial response to Tarlatamab"},{"claim_count":16,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":10,"title":"Secondary endpoints"},{"claim_count":20,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":24,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":18,"title":"The comparison"},{"claim_count":19,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":8,"title":"Safety and tolerability"},{"claim_count":8,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":13,"coverage":"discussed","id":"A1","source_count":5,"title":"Time toxicity, travel and care-provider burden"},{"claim_count":10,"coverage":"discussed","id":"A2","source_count":7,"title":"Observation requirements and patient-support conditions"},{"claim_count":30,"coverage":"discussed","id":"A3","source_count":3,"title":"Relapsed-treatment alternatives, affordability and geographic access"},{"claim_count":23,"coverage":"discussed","id":"A4","source_count":2,"title":"CNS confidence and selective local-versus-systemic treatment"},{"claim_count":15,"coverage":"discussed","id":"A5","source_count":1,"title":"Workforce preparation and equitable treatment reach"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":13,"title":"Attention to the study and the strength of endorsement"},{"claim_count":11,"coverage":"discussed","id":"A7","source_count":4,"title":"Clinical-value interpretation beyond a single radiographic endpoint"}],"counts":{"cited_sources":39,"claims_by_expression_type":{"comparison":25,"experience":10,"interpretation":32,"opinion":64,"primary_context":1,"question":16,"restatement":25,"uncertainty":8,"unspecified":25},"claims_by_kind":{"attributed_opinion":37,"source_observation":169},"clinician_statements":59,"evidence_units":136,"findings":8,"organisational_accounts":7,"people_cited":31,"people_identity_verified":25,"people_total":31,"screened_sources":58,"verified_claims":206},"depth":"rich","findings_index":[{"id":"F1","structure":{"claims":19,"claims_by_group":{"comparisons":5,"experience":0,"questions":0,"restated":7,"views":7},"has_counterview":true,"limitations":2,"links":{"context":3,"support":20},"ma_question":true,"named_voices":8,"passages":16,"sources":13,"sources_by_kind":{"commentary":12,"media":1}},"title":"Interest in longer intervals does not amount to agreement on interchangeable schedules"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":7,"experience":0,"questions":0,"restated":0,"views":3},"has_counterview":true,"limitations":3,"links":{"context":5,"support":10},"ma_question":true,"named_voices":5,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Broad safety reassurance is repeatedly qualified by CRS, ICANS and serious-event observations"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":0,"views":3},"has_counterview":true,"limitations":2,"links":{"context":5,"support":6},"ma_question":true,"named_voices":3,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Non-estimable survival prompts a question about maturity, not a conclusion of treatment success"},{"id":"F4","structure":{"claims":19,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":2,"views":14},"has_counterview":true,"limitations":3,"links":{"context":0,"support":20},"ma_question":true,"named_voices":7,"passages":9,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Visit frequency and initial observation are separate burdens, with different safeguards"},{"id":"F5","structure":{"claims":17,"claims_by_group":{"comparisons":4,"experience":1,"questions":2,"restated":2,"views":8},"has_counterview":true,"limitations":3,"links":{"context":2,"support":18},"ma_question":true,"named_voices":3,"passages":8,"sources":1,"sources_by_kind":{"media":1}},"title":"In resource-limited settings, preferred treatment depends on whether the criterion is experience or deliverability"},{"id":"F6","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":4,"views":10},"has_counterview":true,"limitations":5,"links":{"context":1,"support":17},"ma_question":true,"named_voices":8,"passages":14,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Enthusiasm for later-line tarlatamab is qualified by who can reach and tolerate treatment"},{"id":"F7","structure":{"claims":13,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":0,"views":9},"has_counterview":true,"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":2,"passages":6,"sources":2,"sources_by_kind":{"media":2}},"title":"CNS confidence differs, and local-treatment decisions remain conditional rather than automatic"},{"id":"F8","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":2,"questions":1,"restated":3,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":17},"ma_question":true,"named_voices":4,"passages":9,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Safe delivery is described as a whole-workforce capability, especially outside major centers"}],"medical_affairs_question":"What evidence and patient-service safeguards would make Q3W or Q4W an acceptable trade-off without sacrificing clinically important activity?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Longer intervals: an attractive option, not an agreed universal switch"},{"id":"section-2","level":2,"title":"Safety: retain the specific signals beside the overall reassurance"},{"id":"section-3","level":2,"title":"Survival: encouragement is not the same as maturity"},{"id":"section-4","level":2,"title":"Patient burden: distinguish fewer visits from shorter initial observation"},{"id":"section-5","level":2,"title":"Alternatives and access: the preferred option changes with the criterion"},{"id":"section-6","level":2,"title":"Later-line enthusiasm: selection, attrition and endpoint interpretation remain open"},{"id":"section-7","level":2,"title":"CNS decisions: preserve disagreement and the reasons to defer or add local treatment"},{"id":"section-8","level":2,"title":"Delivery capability: unfamiliar toxicity requires a wider care team"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Proportion of participants with confirmed objective response to Tarlatamab"},{"findings":[],"id":"T2","label":"Primary endpoint: Proportion of participants with complete response to Tarlatamab"},{"findings":[],"id":"T3","label":"Primary endpoint: Proportion of participants with partial response to Tarlatamab"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":5}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F6","shared_claims":14},{"id":"F7","shared_claims":3}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":11},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":5}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":9},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":8}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-27T23:08:53.447446Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-27T23:27:43Z","record_hash":"fc7cdf46973b66d7ec8347ffe4d2af3e89b07ca87733e6a289bfb7e4f50e4cde","release_hash":"3f6f4cc2230a271908f1790dec95f67e258fa3a8876848c96ffa362c856b2bf9","report_id":"erudio-nct06745323","run_id":"ac9c6e15-9465-4ac0-ae64-c9a8f1c99ce2","schema_version":"5.0","slug":"dellphi-309-06745323","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"DeLLphi-309 asks whether less-frequent tarlatamab can maintain treatment benefit in small-cell lung cancer that has progressed after initial chemotherapy. Clinicians in the sources reviewed for this edition express interest in longer intervals without agreement on interchangeable schedules. Dosing flexibility draws enthusiasm, while survival interpretation and treatment burden draw scrutiny. Long-term outcomes and the separate implications of visit frequency and initial observation remain open.","meta_description":"58 sources screened · 206 verified statements (59 from speakers with a confirmed clinical role) from 39 sources · 8 findings. Updated Oct 27, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-7ae21c19795642c1a3f0"],"id":"F3","paraphrase":"A participant in a YouTube discussion asks how to interpret non-estimable overall survival in the longer-interval groups.","publication_caveats":["The questioner's identity and clinical role are not stated in the source."],"source_channel":"youtube","source_date":"2026-09-13","title":"Non-estimable survival prompts a question about maturity, not a conclusion of treatment success"}]},"publication":{"approved_at":"2026-10-27T23:27:43Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":58},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on biomarker-guided patient selection and subtype-specific treatment in small cell lung cancer.","Not yet captured in this edition: a question about financial toxicity in maintenance and subsequent treatment decisions for small cell lung cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","50 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed are not a representative sample of all HCP opinion. Reposts, organizational accounts, repeated summaries and versions of the same discussion must not be counted as independent clinicians or consensus.","Some potentially relevant passages were not fully assessed, and discussion using unnamed or differently transcribed study references may be absent. Missing commentary cannot establish lack of interest or concern.","No full publication for NCT06745323, protocol or exact tarlatamab regulatory label was available for independent reconciliation. Results, regulatory updates and management practices remain attributed accounts where stated.","DeLLphi-309's presented analysis was descriptive, with no hypotheses formally tested. Similarity language does not establish equivalence, and numerical differences do not establish inferiority.","Survival follow-up was approximately nine months in the accounts discussed. Unreached or non-estimable medians do not establish schedule-specific treatment success.","Delivery and hospitalization statements come from different dates, settings and purposes. They should not be combined into a single current administration standard or interpreted as evidence of a change of mind.","Clinical roles are not independently confirmed for several named contributors. A confirmed name or account identity is not confirmation of clinical credentials; the advocate perspective is distinguished from HCP commentary.","Some source passages do not establish who spoke. Their views remain anonymous, and named passages elsewhere do not resolve that uncertainty.","Earlier Phase 3, single-arm or alternative-treatment observations are not DeLLphi-309 results. No schedule-specific CNS conclusion or direct tarlatamab-versus-ADC comparison can be drawn from these discussions.","One duration-of-response value in the press-briefing transcript is unclear. The report does not infer a corrected value from that transcript."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":33,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":39},"count":39,"evidence_window":{"end":"2026-10-14","start":"2025-04-23"},"retrieval_snapshot":"2026-10-27T10:30:31.838450Z","timeline":[{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2025-W26"},{"count":2,"week":"2025-W34"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W35"},{"count":2,"week":"2026-W36"},{"count":20,"week":"2026-W37"},{"count":6,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06745323:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06745323:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pmmp7irwts7faw56jdxk3idc-3mvcruzdjhss2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4e44af","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:89dd7b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c05272","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928472708817252721:a99adec8-e09f-4705-8e6a-31832a86e794","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929528039701967004:c63bbc4d-111c-44b3-9c66-3fc5dd9c303b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1937959146168717719:6adc9ddd-b05e-4504-bd54-69dd3706efc1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957840361818320941:8ad7b5f9-f464-49db-a4dc-6020aa683ca8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1987854132481331309:c0f66096-6735-4429-b319-093f67e8b5cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060132556075672033:82a253bf-06fd-4629-ac9a-7c6729df29be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090801097896312869:1beadd0c-a0cd-437a-ac07-7ad07b301f52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091827865088069697:4d8f761f-eaa9-4cf0-8051-c3e82a27e238","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091887398913212579:2621791e-1598-4746-900c-ef6de98265f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094727184791273781:0ecfc8d6-4fa4-4c6f-8dce-82c7b9b3812b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095089615426236689:33b0d301-1082-4002-8f42-44282f62c0a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095763318904324370:835ad291-0fca-40b6-9837-d9d4bb0aa78e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097127042458304648:9239c772-9b21-42d6-add1-173901b6f747","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097215815351222567:8451de82-450e-4aaa-8def-c2884e337337","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097592038539812875:3a40ccc3-a8c1-4207-8ac6-c1725c24008f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097754324826824786:6172edcf-ca1e-41b2-85f3-99cf09b49af4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097918674418213297:426b93af-ea7d-418c-8076-fa2c99c4d4a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098033900576559146:2296ec0c-e19c-4d51-903e-bacf90c622c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098410360193614302:191b1a18-f30d-45d2-b237-4d5fb1228331","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098466785209049182:0ae8cbe9-27a9-4ed3-94a9-12f0981a6f44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098564723751194810:375c901d-8598-4e32-827e-9ac0b0a254ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098797561393889447:0df27076-eaed-4602-8df7-b7a326aed112","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098824948404109804:3a081dd1-bd37-4878-85f2-b278ba1aaf5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099024078954791072:fc22ea5c-7cfb-4530-8baa-b08b6526ea8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099042290237128792:a18afbfa-d440-4d88-96aa-898cb13d3438","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099044125517709545:b618943c-7273-48ee-a264-71d4d8ddd300","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099044583946555834:68775f68-7866-46d4-bebc-8841e816ab74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099044724414013462:5483872e-c43b-45da-a02f-0c8a2a93d1a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099044990722961640:112117fb-07df-44a2-90ac-8490ea5e999b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099045147480838275:755bc4fa-06d8-4e26-a14b-86b31387e4a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099045293627175248:af022c54-b3ce-4ecd-af06-2714523f5d9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099045841126494521:a6a95e7b-176d-4699-8ebf-2cb3950dc7bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099052356357009506:81e7a5ad-d6b3-4f21-bd7f-fbad9855f114","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099056738649477428:c57295cd-ac77-476c-8aec-f2045b1bf898","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099144847051399661:a03af40d-39e5-4663-b338-8a2408a6efd9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099150433508106514:8cca72e6-65b4-4c55-9767-50e43ae53f27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099207281175077355:6cdd4232-2ed3-4342-8491-2c6db91aec3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099219354923536443:f767d8e4-0510-4755-9b0a-aa0708a2fd8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099219733614657749:de2a8054-2b9a-4b38-842c-32a77047a814","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099287528666787883:ee26ff70-08fb-4625-a3a8-031181215064","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099417673457148331:814f62e3-6922-42e2-8dab-f623e380548d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099744093765034165:2c664c60-0aaa-4967-a606-5c26f0b49bde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099798922684170750:f43cd296-3fcb-47fd-878d-2e06b36b22f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099955219064844426:28b861e0-837b-4cb3-b0ec-4d12846e6e71","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100055568471789801:8d506468-63dc-42d5-8bf4-aaf89e42bfcc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101323692730896744:1518d34b-ca20-48c1-b723-e8e0d215792c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102563649441198321:1a5f1732-998c-4fd7-9889-e68a23ac7bed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107854829456376121:99e40f67-defd-48c1-9e22-db89d86cabc6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110472012598497766:174c94d7-16b7-47f2-a11f-0d850275d855","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:3jB4Oi37oQA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JBaQU96pYTo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Lk4vaEEQg3g","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:XdOZn9k9MQg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:t6Y3RqVo-4o","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":49,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":58},"count":58,"evidence_window":{"end":"2026-10-14","start":"2024-01-08"},"retrieval_snapshot":"2026-10-27T10:30:31.838450Z","timeline":[{"count":1,"week":"2024-W02"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W33"},{"count":3,"week":"2025-W34"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W34"},{"count":2,"week":"2026-W35"},{"count":3,"week":"2026-W36"},{"count":29,"week":"2026-W37"},{"count":8,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: tarlatamab","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Small cell lung cancer","slug":"small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"DeLLphi-309","aliases":["DeLLphi-309","A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)"],"brief_title":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Small Cell Lung Cancer (SCLC)"],"enrollment":{"count":252,"type":"ACTUAL"},"interventions":[{"name":"Tarlatamab","synonyms":["AMG 757"],"type":"DRUG"}],"nct_id":"NCT06745323","official_title":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2029-08-10","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Proportion of participants with confirmed objective response to Tarlatamab","timeFrame":"Approximately 52 Months"},{"measure":"Proportion of participants with complete response to Tarlatamab","timeFrame":"Approximately 52 Months"},{"measure":"Proportion of participants with partial response to Tarlatamab","timeFrame":"Approximately 52 Months"}],"registry_last_updated":"2026-10-06","registry_url":"https://clinicaltrials.gov/study/NCT06745323","short_name":"DeLLphi-309","short_name_basis":"registry_acronym","sponsor":"Amgen","start_date":{"date":"2025-02-26","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"20240092","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}